ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 0960 • ACR Convergence 2024

    The Esophageal Epithelium in Systemic Sclerosis: Cellular and Molecular Dysregulation Revealed by Single-Cell RNA Sequencing

    Matthew Dapas1, Margarette Clevenger1, Hadijat Makinde2, Tyler Therron1, Dustin Carlson1, Mary Carns3, Kathleen Aren3, Carrie Richardson2, Cenfu Wei2, Lutfiyya Muhammad4, John Pandolfino1, Harris Perlman2, Deborah Winter5 and Marie-Pier Tetreault1, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Northwestern Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and progressive fibrosis of the skin and internal organs. Individuals with SSc often…
  • Abstract Number: 1572 • ACR Convergence 2024

    Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis

    Ju Young Lee1, Swapna Joshi2, Arissa Young3, Jen Labus2, Zsuzsanna McMahan4, Ezinne Aja2, Jonathan Jacobs2 and Elizabeth Volkmann5, 1David Geffen School of Medicine, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA, Los Angeles, CA, 4UTHealth Houston Division of Rheumatology, Houston, TX, 5University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

    Background/Purpose: Alterations in the gastrointestinal (GI) microbiome (i.e., dysbiosis) are a feature of systemic sclerosis (SSc) [1]. Diet is a known modifier of the GI…
  • Abstract Number: 1825 • ACR Convergence 2024

    Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis

    Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
  • Abstract Number: 2450 • ACR Convergence 2024

    Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients

    Eva Hoekstra1, S. Ahmed2, David Ueckert3, Nina Ajmone Marsan3, Philippine Kiès3, M.K. Ninaber3, Marlies Heuvers3, Miranda Geelhoed3, Thomas Huizinga4 and Jeska de Vries-Bouwstra1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Leids Universitair Medisch Centrum, Leiden, Netherlands, 4Department of Rheumatology, Leiden University, Leiden, Netherlands

    Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
  • Abstract Number: PP08 • ACR Convergence 2024

    Whispers of Resilience: Navigating Life with Rheumatism

    Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
  • Abstract Number: 0694 • ACR Convergence 2024

    A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database

    Stefano Di Donato1, Michael Hughes2, John Pauling3, Marco Matucci-Cerinic4, Lesley-Anne Bissell5, Edward Jude6, Christopher Denton7, Yannick Allanore8, Marie-Elise Truchetet9 and Francesco Del Galdo10, and EUSTAR collaborators, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, 3North Bristol NHS Trust, Bristol, United Kingdom, 4University San Raffaele Milano, Milano, Milan, Italy, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, 7University College London, Northwood, United Kingdom, 8Université Paris Cité, Paris, France, 9Bordeaux University Hospital, Bordeaux, France, 10University of Leeds, Leeds, United Kingdom

    Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 1573 • ACR Convergence 2024

    Early Scleroderma with Non-Raynaud’s Symptoms Prior to Raynaud’s Onset Is Associated with Rapid Progression to Diffuse Skin Disease and Joint Contractures

    Iqtidar Hanif1, Shervin Assassi1, Maureen Mayes1, Meng Zhang1, Julio Charles1, John VanBuren2, Jessica Alvey2, Kimia Ghaffari2, Elana Bernstein3, Flavia Castelino4, Lorinda Chung5, Luke Evnin6, Tracy Frech7, Jessica Gordon8, Faye Hant9, Laura Hummers10, Dinesh Khanna11, Kimberly Lakin12, Dorota Lebiedz-Odrobina13, Yiming Luo14, Ashima Makol15, Jerry Molitor16, Duncan Moore17, Carrie Richardson18, Nora Sandorfi19, Ami Shah20, Ankoor Shah21, Victoria Shanmugam22, Virginia Steen23, Elizabeth Volkmann24, Carleigh Zahn11 and Brian Skaug1, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2University of Utah, Salt Lake City, UT, 3Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 4Massachusetts General Hospital, Boston, MA, 5Stanford University, Woodside, CA, 6Scleroderma Research Foundation, Brisbane, CA, 7Vanderbilt University Medical Center, Nashville, TN, 8Division of Rheumatology, Weill Cornell Medical College, New York, NY, 9Medical University of South Carolina, Charleston, SC, 10Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 11University of Michigan, Ann Arbor, MI, 12Hospital for Special Surgery, New York, NY, 13University of Utah, Cottonwood Heights, UT, 14Columbia University, New York, NY, 15Mayo Clinic, Rochester, MN, Rochester, MN, 16University of Minnesota, Minneapolis, MN, 17Northwestern Memorial Hospital, Chicago, IL, 18Northwestern University, Chicago, IL, 19University of Pennsylvania, Philadelphia, PA, 20Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 21Duke University, Durham, NC, 22Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, 23Georgetown University School of Medicine, Washington, DC, 24University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

    Background/Purpose: Raynaud’s phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc).  RP alerts clinicians to the possibility of an autoimmune rheumatic disease,…
  • Abstract Number: 1826 • ACR Convergence 2024

    Unveiling the Primary Cilia Signature Driving Systemic Sclerosis Pathogenesis

    Le My Tu Nguyen1, Carlos Córdova-Fletes2, Poulami Dey3, Johann Gudjonsson3, Rebecca Wells4, Rebecca Ross5, Natalia Riobo-Del Galdo4, Francesco Del Galdo4, Dibyendu Bhattacharyya3, John Varga3 and Maria Teves1, 1Virginia Commonwealth University, Richmond, VA, 2Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3University of Michigan, Ann Arbor, MI, 4University of Leeds, Leeds, United Kingdom, 5Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Fibrosis in multiple organs is the defining hallmark that accounts for the high mortality associated with systemic sclerosis (SSc). Understanding how SSc patients develop…
  • Abstract Number: 2453 • ACR Convergence 2024

    Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study

    Elvira Lesmana1, Ashley Keehn2, Anukul Karn3, Andrea Pauly4, Margaret Breen-Lyles2, Adam L Edwinson2, Madhusudan Grover5 and Ashima Makol5, 1Mayo Clinic, Rochester, MN, New York, NY, 2Mayo Clinic, Rochester, MN, Rochester, 3Mayo Clinic, Rochester, MN, Farmington Hills, MI, 4Mayo Clinic Rochester, Rochester, MN, 5Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
  • Abstract Number: PP11 • ACR Convergence 2024

    Living Well with Chronic Illness: Decades with MCTD

    Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC

    Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
  • Abstract Number: 0695 • ACR Convergence 2024

    Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

    Stefano Di Donato1, Marco Minerba2, Enrico De Lorenzis3, Collette Hartley4, Lesley-Anne Bissell5, Rebecca Ross6 and Francesco Del Galdo4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Campus Bio-Medico University of Rome, Taranto, United Kingdom, 3Catholic University of the Sacred Heart, Roma, Rome, Italy, 4University of Leeds, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
  • Abstract Number: 0965 • ACR Convergence 2024

    Scleroderma Associated Interstitial Lung Disease Is Characterized by Aberrant Lung Epithelial Remodeling

    Monica Yang1, Fred Deiter2, Emily Flynn2, Seoyeon Lee3, Jessica Neely1, John Greenland2, Marina Sirota2 and Paul Wolters2, 1UCSF, San Francisco, CA, 2UCSF, SF, 3Yale, New Haven

    Background/Purpose: Interstitial lung disease (ILD) is present in a majority of systemic sclerosis (SSc) patients and the leading cause of SSc-related mortality. A subset of…
  • Abstract Number: 1577 • ACR Convergence 2024

    Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog

    Neda Kortam1, Wenying Liang1, Claire Shiple1, Suiyuan Huang1, Rosemary Gedert1, James St. Clair1, Cyrus Sarosh2, Caroline Foster1, Eliza Pei-Suen Tsou1, John Varga1, Jason Knight1, Dinesh Khanna1 and Ramadan Ali1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI

    Background/Purpose: Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We…
  • Abstract Number: 1829 • ACR Convergence 2024

    Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis

    Philip Yee1, Medha Kanitkar2, Kristina Clark3, Voon Ong1 and Christopher Denton4, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University College London, Northwood, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) displays significant heterogeneity. Those with limited cutaneous systemic sclerosis (lcSSc) experience significant systemic organ involvement similar to those with diffuse cutaneous…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology